The effects of erythromycin on the electrocardiogram

Archana Mishra, Howard S. Friedman, Anjan Sinha

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Various cardiac electrophysiologic effects have been attributed to erythromycin. During the course of treating a pneumonia patient with IV erythromycin, the conversion of atrial fibrillation to a sinus rhythm, and its subsequent reversal, appeared to be causally related to the introduction and cessation of this antibiotic. Objective: This observation suggested the need for studying the changes in the ECG following the use of IV erythromycin in a typical clinical setting. Design: A prospective comparative drug study. Setting: A university-affiliated teaching hospital. Patients: Nineteen patients being treated for uncomplicated community- acquired pneumonia. Intervention: IV erythromycin, 500 mg, and/or IV cefuroxime, 750 mg, infused in 250 mL of saline over 20 min. In the 11 patients who were receiving both of the antibiotics, cefuroxime was administered immediately before erythromycin was infused. Measurements: The 12-lead ECG measurements were obtained before infusion, at 5-min intervals during each infusion, and at 5 and 10 min after the infusions had been completed. All of the ECG complexes and intervals were measured using a software program (Interpretive Cardiograph; Hewlett Packard; Palo Alto, CA). Results: The administration of IV erythromycin increased heart rate and prolonged the corrected QT (QTc) interval. These changes were significant at 15 min of the infusion, and were no longer evident 5 min after the infusion had been stopped. The administration of IV cefuroxime did not produce any ECG changes. Conclusions: A single, standard dose of IV erythromycin prolongs the QTc interval; therefore, the drug should always be administered as a slow infusion. ECG monitoring should accompany erythromycin therapy in critically ill patients, in patients with electrolyte disorders, or in patients taking other drugs with similar cardiac effects.

Original languageEnglish (US)
Pages (from-to)983-986
Number of pages4
JournalChest
Volume115
Issue number4
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Erythromycin
Electrocardiography
Cefuroxime
Pneumonia
Pharmaceutical Preparations
Anti-Bacterial Agents
Critical Illness
Teaching Hospitals
Atrial Fibrillation
Electrolytes
Software
Heart Rate

Keywords

  • Corrected QT interval
  • Electrocardiogram
  • Erythromycin
  • Torsade de pointes

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The effects of erythromycin on the electrocardiogram. / Mishra, Archana; Friedman, Howard S.; Sinha, Anjan.

In: Chest, Vol. 115, No. 4, 1999, p. 983-986.

Research output: Contribution to journalArticle

Mishra, Archana ; Friedman, Howard S. ; Sinha, Anjan. / The effects of erythromycin on the electrocardiogram. In: Chest. 1999 ; Vol. 115, No. 4. pp. 983-986.
@article{799e6e3e05cb4d9691676fd01566f377,
title = "The effects of erythromycin on the electrocardiogram",
abstract = "Background: Various cardiac electrophysiologic effects have been attributed to erythromycin. During the course of treating a pneumonia patient with IV erythromycin, the conversion of atrial fibrillation to a sinus rhythm, and its subsequent reversal, appeared to be causally related to the introduction and cessation of this antibiotic. Objective: This observation suggested the need for studying the changes in the ECG following the use of IV erythromycin in a typical clinical setting. Design: A prospective comparative drug study. Setting: A university-affiliated teaching hospital. Patients: Nineteen patients being treated for uncomplicated community- acquired pneumonia. Intervention: IV erythromycin, 500 mg, and/or IV cefuroxime, 750 mg, infused in 250 mL of saline over 20 min. In the 11 patients who were receiving both of the antibiotics, cefuroxime was administered immediately before erythromycin was infused. Measurements: The 12-lead ECG measurements were obtained before infusion, at 5-min intervals during each infusion, and at 5 and 10 min after the infusions had been completed. All of the ECG complexes and intervals were measured using a software program (Interpretive Cardiograph; Hewlett Packard; Palo Alto, CA). Results: The administration of IV erythromycin increased heart rate and prolonged the corrected QT (QTc) interval. These changes were significant at 15 min of the infusion, and were no longer evident 5 min after the infusion had been stopped. The administration of IV cefuroxime did not produce any ECG changes. Conclusions: A single, standard dose of IV erythromycin prolongs the QTc interval; therefore, the drug should always be administered as a slow infusion. ECG monitoring should accompany erythromycin therapy in critically ill patients, in patients with electrolyte disorders, or in patients taking other drugs with similar cardiac effects.",
keywords = "Corrected QT interval, Electrocardiogram, Erythromycin, Torsade de pointes",
author = "Archana Mishra and Friedman, {Howard S.} and Anjan Sinha",
year = "1999",
doi = "10.1378/chest.115.4.983",
language = "English (US)",
volume = "115",
pages = "983--986",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4",

}

TY - JOUR

T1 - The effects of erythromycin on the electrocardiogram

AU - Mishra, Archana

AU - Friedman, Howard S.

AU - Sinha, Anjan

PY - 1999

Y1 - 1999

N2 - Background: Various cardiac electrophysiologic effects have been attributed to erythromycin. During the course of treating a pneumonia patient with IV erythromycin, the conversion of atrial fibrillation to a sinus rhythm, and its subsequent reversal, appeared to be causally related to the introduction and cessation of this antibiotic. Objective: This observation suggested the need for studying the changes in the ECG following the use of IV erythromycin in a typical clinical setting. Design: A prospective comparative drug study. Setting: A university-affiliated teaching hospital. Patients: Nineteen patients being treated for uncomplicated community- acquired pneumonia. Intervention: IV erythromycin, 500 mg, and/or IV cefuroxime, 750 mg, infused in 250 mL of saline over 20 min. In the 11 patients who were receiving both of the antibiotics, cefuroxime was administered immediately before erythromycin was infused. Measurements: The 12-lead ECG measurements were obtained before infusion, at 5-min intervals during each infusion, and at 5 and 10 min after the infusions had been completed. All of the ECG complexes and intervals were measured using a software program (Interpretive Cardiograph; Hewlett Packard; Palo Alto, CA). Results: The administration of IV erythromycin increased heart rate and prolonged the corrected QT (QTc) interval. These changes were significant at 15 min of the infusion, and were no longer evident 5 min after the infusion had been stopped. The administration of IV cefuroxime did not produce any ECG changes. Conclusions: A single, standard dose of IV erythromycin prolongs the QTc interval; therefore, the drug should always be administered as a slow infusion. ECG monitoring should accompany erythromycin therapy in critically ill patients, in patients with electrolyte disorders, or in patients taking other drugs with similar cardiac effects.

AB - Background: Various cardiac electrophysiologic effects have been attributed to erythromycin. During the course of treating a pneumonia patient with IV erythromycin, the conversion of atrial fibrillation to a sinus rhythm, and its subsequent reversal, appeared to be causally related to the introduction and cessation of this antibiotic. Objective: This observation suggested the need for studying the changes in the ECG following the use of IV erythromycin in a typical clinical setting. Design: A prospective comparative drug study. Setting: A university-affiliated teaching hospital. Patients: Nineteen patients being treated for uncomplicated community- acquired pneumonia. Intervention: IV erythromycin, 500 mg, and/or IV cefuroxime, 750 mg, infused in 250 mL of saline over 20 min. In the 11 patients who were receiving both of the antibiotics, cefuroxime was administered immediately before erythromycin was infused. Measurements: The 12-lead ECG measurements were obtained before infusion, at 5-min intervals during each infusion, and at 5 and 10 min after the infusions had been completed. All of the ECG complexes and intervals were measured using a software program (Interpretive Cardiograph; Hewlett Packard; Palo Alto, CA). Results: The administration of IV erythromycin increased heart rate and prolonged the corrected QT (QTc) interval. These changes were significant at 15 min of the infusion, and were no longer evident 5 min after the infusion had been stopped. The administration of IV cefuroxime did not produce any ECG changes. Conclusions: A single, standard dose of IV erythromycin prolongs the QTc interval; therefore, the drug should always be administered as a slow infusion. ECG monitoring should accompany erythromycin therapy in critically ill patients, in patients with electrolyte disorders, or in patients taking other drugs with similar cardiac effects.

KW - Corrected QT interval

KW - Electrocardiogram

KW - Erythromycin

KW - Torsade de pointes

UR - http://www.scopus.com/inward/record.url?scp=0032929747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032929747&partnerID=8YFLogxK

U2 - 10.1378/chest.115.4.983

DO - 10.1378/chest.115.4.983

M3 - Article

C2 - 10208196

AN - SCOPUS:0032929747

VL - 115

SP - 983

EP - 986

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4

ER -